PharmaNutra SpA, the Healthcare sector company, was revisited by a Wall Street analyst on September 9. Analyst Corentin Marty from TP ICAP MIDCAP maintained a Buy rating on the stock and has a €74.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Corentin Marty has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s strong performance and promising outlook. The company’s sales for the first half of 2025 increased by 10.7% to €61.9 million, aligning with expectations, while its EBITDA reached €16.5 million. This growth was largely driven by international activities, which saw a 12.5% year-over-year increase, and solid domestic performance.
Additionally, the company’s strategic investments in new markets such as the USA and China have begun to yield positive results, contributing notably to revenue. The introduction of new products like Sidevit® B12 has also shown promising market penetration. Despite a challenging macroeconomic environment, management remains optimistic about achieving double-digit growth, supported by strong international contributions. These factors, alongside a stable EBITDA margin, underpin the Buy recommendation, positioning PharmaNutra as a top pick in the current market scenario.
According to TipRanks, Marty is ranked #5408 out of 9983 analysts.
In another report released on September 9, Intermonte also maintained a Buy rating on the stock with a €84.00 price target.